Highlights

• Heavy lanthanides (Gd, Dy, Tb, Ho, Er, Lu) are critical to over 30 million annual MRI scans, X-ray detectors, surgical lasers, and cancer theranostics. Healthcare relies on imports for 80% of these minerals.
• China's April 2025 export licensing on Gd, Tb, Dy, Lu, and Y creates acute supply-chain risk for medical OEMs like GE HealthCare, Siemens, and radiopharma leaders including Novartis.
• Efforts to diversify supply through non-Chinese separation, U.S. processing, and recycling are underway, but scaling remains uncertain amid price volatility and narrow feedstock availability.

---

Heavy lanthanides (e.g., gadolinium [Gd], dysprosium [Dy], terbium [Tb], holmium [Ho], erbium [Er], lutetium [Lu]) are critical inputs across modern medical imaging, diagnostics, and therapeutics. Gadolinium-based contrast agents (GBCAs) alone are used in approximately 30 million MRI scans globally each year, enhancing soft-tissue visualization. Total global gadolinium oxide demand across all industries is estimated at ~800–1,200 metric tons per year, with medical imaging representing a significant downstream share.

Because gadolinium is not mined independently but recovered as a by-product of rare earth processing, supply depends heavily on upstream separation capacity. Studies suggest an average MRI system administers only a few kilograms of gadolinium annually; environmental monitoring indicates that regional healthcare systems collectively discharge tens to hundreds of kilograms per year into wastewater streams, underscoring both scale and supply sensitivity.

Beyond MRI contrast, heavy REEs such as Tb, Eu, Y, and Gd are embedded in X-ray and CT detector phosphors that deliver higher brightness and resolution. NdFeB permanent magnets—often doped with Dy or Tb to improve thermal stability—are used in motors, actuators, and components across imaging platforms. Global NdFeB magnet production is estimated at ~200,000 metric tons annually, with heavy REEs representing small but strategically critical additives.

In surgical medicine, Er:YAG and Ho:YAG lasers are standard tools in dermatology, dentistry, ophthalmology, and urology. These systems rely on crystals doped with heavy lanthanides, materials that are highly specialized and difficult to substitute. In oncology, lutetium-177 has become central to “theranostic” radiopharmaceuticals, including Novartis’s Lutathera and Pluvicto. While Lu-177 demand is measured in radioactivity units (terabecquerels), upstream requirements translate into meaningful quantities of high-purity lutetium feedstock, straining an already narrow supply base.

Supply-Chain Risk and Policy Exposure

Healthcare stakeholders increasingly recognize rare earths as a critical supply-chain vulnerability. The American Hospital Association has warned that U.S. healthcare relies on imports for roughly 80% of critical minerals, including rare earths essential to imaging and radiopharma. China dominates not only mining but nearly all heavy rare earth refining, making downstream medical technologies acutely exposed.

This risk sharpened in April 2025, when China imposed export licensing requirements on several medium and heavy rare earths, including Gd, Tb, Dy, Lu, Sm, Sc, and Y. While not a formal ban, these controls grant Beijing discretionary leverage over supply. Legal and industry analysts have warned of sharp price volatility; in one high-profile example, yttrium oxide prices surged dramatically following the controls, illustrating how quickly medical input costs can spike.

Industry Response

Medical OEMs such as GE HealthCare, Siemens Healthineers, Philips, Canon Medical, and Hitachi all depend on heavy REEs across imaging platforms. GE has publicly acknowledged reliance on Chinese-sourced gadolinium and has accelerated “China+1” manufacturing strategies. Surgical laser firms (Lumenis, Alma, Cynosure) and radiopharma leaders (Novartis, ITM, Curium) are likewise monitoring supply exposure.

In parallel, governments and industry are funding alternative supply routes—non-Chinese separation (Lynas, Iluka), U.S. processing (MP Materials), magnet and oxide recycling (Apple/MP, Ionic Rare Earths), and EU-based isotope production. Whether these efforts scale fast enough remains uncertain.

REEx take: heavy rare earths are quite enablers of modern medicine. Without durable diversification beyond China, shortages or price shocks risk slowing innovation across imaging, surgery, and cancer care.

© 2025 Rare Earth Exchanges™ – Accelerating Transparency, Accuracy, and Insight Across the Rare Earth & Critical Minerals Supply Chain.